These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2623545)

  • 21. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome.
    Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD; Mikhailidis DP; Jeremy JY; Dandona P
    Prostaglandins Leukot Med; 1985 Jun; 18(3):401-2. PubMed ID: 3895252
    [No Abstract]   [Full Text] [Related]  

  • 22. Arteriolar resistance and hemorheological disorders related to Raynaud's phenomenon.
    Mchedlishvili G; Mantskava M; Pargalava N
    Microvasc Res; 2001 Sep; 62(2):190-5. PubMed ID: 11516248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous microcirculation in systemic sclerosis and response to intra-arterial reserpine.
    Nilsen KH; Jayson MI
    Br Med J; 1980 Jun; 280(6229):1408-11. PubMed ID: 7427134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated homocysteine levels in patients with Raynaud's syndrome.
    Danese S; Candelli M; Gasbarrini A
    J Rheumatol; 2000 Aug; 27(8):2051. PubMed ID: 10955356
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.
    Dowd PM; Kovacs IB; Bland CJ; Kirby JD
    Br Med J (Clin Res Ed); 1981 Aug; 283(6287):350. PubMed ID: 6788326
    [No Abstract]   [Full Text] [Related]  

  • 29. Altered microrheological parameters in Raynaud's phenomenon.
    Papp J; Sandor B; Toth A; Biro K; Rabai M; Botor D; Kovacs D; Csernus Z; Toth K; Kesmarky G
    Clin Hemorheol Microcirc; 2017; 65(1):23-29. PubMed ID: 27258205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vital microscopy of nailfold capillaries in progressive scleroderma in relation to the clinical picture].
    Arizpe SR; Hornstein OP; Deinlein E
    Z Hautkr; 1984 May; 59(9):593-600. PubMed ID: 6730614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon.
    Biondi ML; Marasini B; Bianchi E; Agostoni A
    Int J Cardiol; 1988 Jun; 19(3):335-9. PubMed ID: 3397197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?
    Ingegnoli F; Gualtierotti R; Schioppo T; Orenti A; Boracchi P; Lubatti C; Mastaglio C; Galbiati V; Murgo A; Zeni S; Grossi C; Borghi O; Rosenberg W; Castelnovo L; Meroni Pier L
    Ann Rheum Dis; 2014 May; 73(5):940-1. PubMed ID: 24344159
    [No Abstract]   [Full Text] [Related]  

  • 35. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local cooling test for clinical capillaroscopy in Raynaud's phenomenon.
    Mahler F; Saner H
    Vasa Suppl; 1989; 27():27-8. PubMed ID: 2623512
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.
    Pauling JD; O'Donnell VB; Mchugh NJ
    Platelets; 2013; 24(7):503-15. PubMed ID: 22966961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon.
    Pancera P; Sansone S; Presciuttini B; Montagna L; Cerù S; Lunardi C; Lechi A
    Clin Sci (Lond); 1999 Jan; 96(1):49-57. PubMed ID: 9857106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raynaud's phenomenon in mixed connective tissue disease.
    Grader-Beck T; Wigley FM
    Rheum Dis Clin North Am; 2005 Aug; 31(3):465-81, vi. PubMed ID: 16084319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.